Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Pretreatment prognostic factors and early markers for outcome in advanced melanoma treated with nivolumab

Date

09 Oct 2016

Session

Poster display

Presenters

Yoshio Nakamura

Citation

Annals of Oncology (2016) 27 (6): 379-400. 10.1093/annonc/mdw379

Authors

Y. Nakamura1, S. Kitano2, A. Takahashi1, A. Tsutsumida1, K. Namikawa1, I. Muto1, M. Ueno1, Y. Muto1, N. Yamazaki1

Author affiliations

  • 1 Dermatologic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Experimental Therapeutics, National Cancer Center Hospital, 104-0045 - Tokyo/JP
More

Resources

Abstract 1174

Background

Anti-programmed cell death protein 1(PD-1) monoclonal antibody, nivolumab, is one of the most effective drugs for advanced melanoma. Serum lactate dehydrogenase (LDH) and cutaneous adverse events have been described as early predictors for outcomes of advanced melanoma treated with nivolumab in some literature. We tried to seek further clinical predictors in daily clinical practice.

Methods

We retrospectively analyzed clinical findings of 54 unresectable stage III or IV melanoma patients treated with nivolumab at the National Cancer Center Hospital, Tokyo, Japan, between September 2014 and December 2015. The patients who took steroid orally were excluded from this study. Those patients were administered nivolumab at a dose of 2mg/kg every 3 weeks.

Results

Median overall survival (OS) was 12.7 months. Response rate was 25.9%. Delayed response was shown in only one patient. Patients with baseline ECOG performance status (PS) =0, baseline normal LDH and baseline normal C-related protein (CRP) had significantly longer OS compared with patients with PS ≥ 1 (hazard ratio[HR] 0.25, 95%CI 0.09-0.68, P 

Conclusions

Delayed response may rarely occur in daily clinical practice. ALC ≥ 1000/ml and NLR 

Clinical trial identification

Legal entity responsible for the study

National Cancer Center Hospital

Funding

National Cancer Center Hospital

Disclosure

N. Yamazaki: Advisory board role for Chugai Pharma, Bristol-Myers Squibb (BMS) Japan and Ono Pharmaceutical. The institution has received clinical trial support from Chugai, BMS Japan, Ono, GSK, Takeda, AstraZeneca Japan, Boehringer Ingelheim, and Maruho. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings